LIXTE BIOTECHNOLOGY HOLDINGS, INC. 10-K Cybersecurity GRC - 2025-03-24

Page last updated on March 24, 2025

LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported their cybersecurity risk management and governance process in a yearly 10-K filed on 2025-03-24 08:30:38 EDT.

Filings

10-K filed on 2025-03-24

LIXTE BIOTECHNOLOGY HOLDINGS, INC. filed a 10-K at 2025-03-24 08:30:38 EDT
Accession Number: 0001641172-25-000208

Note: filing items unformatted. Drop us a note with the above URL to help us prioritize formatting it!

Item 1C. Cybersecurity.

ITEM 1C. CYBERSECURITY Risk Management and Strategy We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management systems and processes. We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information and email systems that may result in adverse effects on the confidentiality, integrity, or availability of our information and email systems or any information residing therein. We conduct periodic risk assessments to identify cybersecurity threats, as well as assessments in the event of a material change in our business practices that may affect information systems that are vulnerable to such cybersecurity threats. These risk assessments include identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks. -53- Following these risk assessments, we intend to take any steps necessary to redesign, implement, and maintain reasonable safeguards to minimize identified risks; to reasonably address any identified gaps in existing safeguards; and to regularly monitor the effectiveness of our safeguards. Primary responsibility for assessing, monitoring and managing our cybersecurity risks rests with an IT consultant, who reports to our Chief Executive Officer and Chief Financial Officer, to manage the risk assessment and mitigation process. As part of our overall risk management system, we monitor and periodically evaluate our safeguards. We may engage consultants, or other third parties in connection with our risk assessment processes. These service providers can assist us to design and implement our cybersecurity policies and procedures, as well as to monitor and test our safeguards. To date, we have not encountered cybersecurity challenges that have materially impaired our operations or financial condition. Additional information regarding risks from cybersecurity threats is provided at “Item 1A. Risk Factors”. Governance One of the functions of our Board of Directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our Board of Directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks that we face. Our Board of Directors administers its cybersecurity risk oversight function directly as a whole, as well as through the audit committee. Our Chief Executive Officer and Chief Financial Officer are primarily responsible to assess and manage our material risks from cybersecurity threats with assistance from third-party service providers. Our Chief Executive Officer and Chief Financial Officer interact with our IT consultant and oversee our cybersecurity policies and processes, including those described above at “Risk Management and Strategy”. The cybersecurity risk management program includes tools and activities to prevent, detect, and analyze current and emerging cybersecurity threats, and plans and strategies to address threats and incidents. Our Chief Executive Officer and Chief Financial Officer provide periodic briefings to the audit committee regarding the Company’s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and similar issues.


Company Information

NameLIXTE BIOTECHNOLOGY HOLDINGS, INC.
CIK0001335105
SIC DescriptionPharmaceutical Preparations
TickerLIXT - NasdaqLIXTW - Nasdaq
Website
CategoryNon-accelerated filer
Smaller reporting company
Fiscal Year EndDecember 30